Business · Companies · 1 hr ago

AriBio-Linked Shares Fall After Alzheimer’s Drug Trial Results

AriBio-Linked Shares Fall After Alzheimer’s Drug Trial Results

AriBio-linked shares fell sharply in early trading on Nov.

17.

AriBio, a South Korean biotechnology company, is developing an oral treatment for Alzheimer’s disease.

The drug was tested in a global phase 3 clinical trial, a late-stage test of a treatment.

It met the trial’s pre-set primary target, but did not statistically prove a treatment effect in the overall patient group.

AriBio Lab shares were down 17.30% at 9:06 a.m., compared with the previous day.

The results show that meeting the trial’s main target did not establish a statistically significant effect across all patients.

1 source

Related